clopidogrel has been researched along with Body Weight in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q | 1 |
| Abdolhoseini, M; Hinwood, M; Hood, RJ; Johnson, SJ; Martin, K; Nilsson, M; Paul, JW; Paul, M; Pollack, M; Walker, FR | 1 |
| Abe, K; Ikeda, Y; Kitagawa, K; Kitazono, T; Nanto, S; Nishikawa, M; Ogawa, A; Toyoda, K | 1 |
| Atar, S; Bernaud, C; Fahrni, G; Frenoux, JM; Hmissi, A; Moccetti, T; Mueller, C; Schelfaut, D; Sinnaeve, P; Spirito, A; Ufer, M; Valgimigli, M | 1 |
| Dong, W; He, X; Hu, H; Kong, Y; Li, Y; Li, Z; Sun, L; Wang, C; Wang, Y; Yang, D; Zhang, J; Zhao, M | 1 |
| Court, MH; Faus, MCL; Lee, PM | 1 |
| Angiolillo, DJ; Bergmeijer, TO; Brown, P; Erlinge, D; Jakubowski, JA; James, S; Moser, BA; Small, DS; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Angiolillo, DJ; Brown, PB; Erlinge, D; Jakubowski, JA; James, S; Moser, BA; Small, DS; Ten Berg, JM; Winters, KJ; Zhou, C | 1 |
| Vengoechea, F | 1 |
| Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weber, S; Zhou, Q | 1 |
| Al-Zumyli, R; Arafat, T; Bulatova, NR; Yousef, AM | 1 |
| Beckerman, P; Ben-Artzi, M; Ben-Yehuda, A; Haber, G; Levin, A; Muszkat, M; Varon, D | 1 |
| Antonino, MJ; Gurbel, PA; Tantry, US | 1 |
| Aleil, B; Cazenave, JP; Gachet, C; Léon, C | 1 |
| Hirata, K; Momose, A; Nakajima, K; Sasaki, N; Shinohara, M; Takeda, M; Tawa, H; Yamashita, T | 1 |
| Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M | 1 |
| Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N | 1 |
| Crimizade, U; El Ghannudi, S; Gachet, C; Hess, S; Jesel, L; Morel, O; Ohlmann, P; Radulescu, B; Reydel, A; Wiesel, ML | 1 |
| Minematsu, K; Tanahashi, N; Uchiyama, S | 1 |
| Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
| Abrams, J; Berra, K; Blankenship, JC; Dallas, AP; Douglas, PS; Fihn, SD; Foody, JM; Gardin, JM; Gerber, TC; Hinderliter, AL; King, SB; Kligfield, PD; Krumholz, HM; Kwong, RY; Lim, MJ; Linderbaum, JA; Mack, MJ; Munger, MA; Prager, RL; Sabik, JF; Shaw, LJ; Sikkema, JD; Smith, CR; Smith, SC; Spertus, JA; Williams, SV | 1 |
| Alfonso, F; Angiolillo, DJ; Barrera Ramírez, C; Bernardo, E; Escaned, J; Fernandez, C; Fernández-Ortiz, A; Hernández-Antolín, R; Macaya, C; Sabaté, M | 1 |
| Patel, MR; Peterson, ED | 1 |
| Goodall, AH; Hayes, PD; Jones, CI; Naylor, AR; Payne, DA | 1 |
2 review(s) available for clopidogrel and Body Weight
| Article | Year |
|---|---|
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.
Topics: Animals; Body Weight; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2009 |
8 trial(s) available for clopidogrel and Body Weight
| Article | Year |
|---|---|
Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II.
Topics: Age Factors; Aged; Aged, 80 and over; Asian People; Body Weight; Brain Ischemia; Clopidogrel; Double-Blind Method; Female; Health Status; Hemorrhage; Humans; Incidence; Japan; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2020 |
Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
Topics: Adult; Aged; Aged, 80 and over; Body Weight; Clopidogrel; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Organophosphonates; Patient Safety; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyrimidines; Ticagrelor; Treatment Outcome | 2020 |
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
Topics: Administration, Oral; Adult; Area Under Curve; Body Weight; Clopidogrel; Drug Interactions; Half-Life; Humans; Male; Platelet Aggregation Inhibitors; Smoking; Ticlopidine | 2008 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinolytic Agents; Humans; Hypertension; Injections, Intravenous; Logistic Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Predictive Value of Tests; Registries; Risk Factors; Stroke; Ticlopidine; Tissue Plasminogen Activator | 2012 |
Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.
Topics: Age Factors; Aged; Asian People; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticlopidine; Treatment Outcome | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Body Weight; Clopidogrel; Endarterectomy, Carotid; Humans; Placebos; Platelet Activation; Platelet Aggregation Inhibitors; Postoperative Complications; Statistics as Topic; Thrombosis; Ticlopidine | 2007 |
15 other study(ies) available for clopidogrel and Body Weight
| Article | Year |
|---|---|
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Platelet Aggregation Inhibitors; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stroke; Ticlopidine; Treatment Outcome | 2022 |
Clopidogrel Administration Impairs Post-Stroke Learning and Memory Recovery in Mice.
Topics: Body Weight; Clopidogrel; Cognition; Humans; Male; Platelet Aggregation Inhibitors; Stroke | 2023 |
Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance.
Topics: Aged; Aspirin; Body Weight; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genotype; Humans; Ischemic Stroke; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Purinergic P2Y12 | 2020 |
High interindividual variability in plasma clopidogrel active metabolite concentrations in healthy cats is associated with sex and cytochrome P450 2C genetic polymorphism.
Topics: Animals; Body Weight; Cats; Chromatography, High Pressure Liquid; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Genotyping Techniques; Male; Polymorphism, Genetic; Sex Factors; Tandem Mass Spectrometry | 2019 |
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Topics: Adult; Aged; Biomarkers; Blood Platelets; Body Mass Index; Body Size; Body Surface Area; Body Weight; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Retrospective Studies; Ticlopidine; Treatment Outcome | 2014 |
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Topics: Adenosine; Body Weight; Clopidogrel; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Inpatients; Length of Stay; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Risk Factors; Sex Factors; Ticlopidine; Treatment Outcome; Warfarin | 2009 |
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Body Weight; Clopidogrel; Comorbidity; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Monitoring; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polypharmacy; Smoking; Ticlopidine; Vasodilator Agents | 2009 |
Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Brachiocephalic Trunk; Cell Adhesion Molecules; Cholesterol, Dietary; Cilostazol; Clopidogrel; Collagen; Cytokines; Disease Models, Animal; Gene Expression Regulation; Immunohistochemistry; Inflammation Mediators; Lipids; Macrophages; Mice; Mice, Knockout; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Ticlopidine; Tomography, X-Ray Computed | 2012 |
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting.
Topics: Aspirin; Body Mass Index; Body Weight; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; Female; Fibrinolytic Agents; Humans; Intracranial Aneurysm; Male; Middle Aged; Retrospective Studies; Risk Factors; Stents; Thrombolytic Therapy; Ticlopidine; Treatment Failure | 2011 |
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Female; Flow Cytometry; Glycated Hemoglobin; Humans; Inflammation; Leukocyte Count; Leukocytes; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphorylation; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2012 |
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight; Cholesterol, LDL; Clopidogrel; Comorbidity; Cost of Illness; Depression; Diabetes Complications; Disease Management; Electrocardiography; Exercise; Exercise Test; Glycated Hemoglobin; Health Behavior; Humans; Hypertension; Life Style; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Physical Examination; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Risk Factors; Risk Reduction Behavior; Smoking Cessation; Ticlopidine | 2012 |
Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
Topics: Aged; Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Spain; Stents; Ticlopidine; Treatment Outcome; Weights and Measures | 2004 |
Clopidogrel dosing in overweight patients: does one size fit all?
Topics: Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Stenosis; Dose-Response Relationship, Drug; Humans; Obesity; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2004 |